Aaron Freidin Sells 45,806 Shares of GRAIL (NASDAQ:GRAL) Stock

GRAIL, Inc. (NASDAQ:GRAL) CFO Aaron Freidin sold 45,806 shares of the firm’s stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total transaction of $2,286,635.52. Following the transaction, the chief financial officer owned 260,669 shares in the company, valued at $13,012,596.48. This represents a 14.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Aaron Freidin also recently made the following trade(s):

• On Monday, March 9th, Aaron Freidin sold 2,492 shares of GRAIL stock. The shares were sold at an average price of $47.89, for a total transaction of $119,341.88.
• On Thursday, March 5th, Aaron Freidin sold 655 shares of GRAIL stock. The shares were sold at an average price of $53.01, for a total transaction of $34,721.55.
• On Monday, March 2nd, Aaron Freidin sold 9,573 shares of GRAIL stock. The shares were sold at an average price of $50.17, for a total transaction of $480,277.41.

GRAIL Trading Down 4.1%

GRAIL stock opened at $45.63 on Friday. The company has a market capitalization of $1.87 billion, a P/E ratio of -4.08 and a beta of 4.62. The firm’s fifty day simple moving average is $63.91 and its 200-day simple moving average is $79.53. GRAIL, Inc. has a 1-year low of $22.30 and a 1-year high of $118.84.

GRAIL (NASDAQ:GRAL) last released its quarterly earnings results on Thursday, February 19th. The company reported ($2.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.33) by $0.89. The business had revenue of $43.60 million for the quarter, compared to the consensus estimate of $43.33 million. GRAIL had a negative net margin of 277.46% and a negative return on equity of 17.11%. On average, equities research analysts predict that GRAIL, Inc. will post -15.15 earnings per share for the current year.

Trending Headlines about GRAIL

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: Analyst consensus remains constructive: Street coverage still shows an average rating of “Moderate Buy” with a consensus price target around $72.83, implying meaningful upside from current levels. Article Title
• Neutral Sentiment: Mizuho initiated coverage with a “neutral” rating and a $58 price target (roughly mid‑teens to low‑20s % upside vs. current quoted levels); the call is cautious and reflects uncertainty rather than outright bullishness. Article Title
• Neutral Sentiment: Piper Sandler also initiated coverage with a “neutral” rating and a $54 price target, signaling analyst caution and limited near‑term conviction. Article Title
• Negative Sentiment: Reported study setback: coverage initiation notes reference a recent study disappointment that prompted the neutral stances — clinical execution and near‑term data risk are now front and center for investors. Article Title
• Negative Sentiment: Insider selling by senior management: CEO, President and CFO sold sizable blocks on April 8 (CEO ~123,502 shares; President ~61,665; CFO ~45,806), materially reducing their holdings — a strong negative signal to the market and a likely contributor to downward pressure. Article Title

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on GRAL shares. Morgan Stanley cut their target price on shares of GRAIL from $110.00 to $60.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 24th. Robert W. Baird set a $82.00 price target on GRAIL in a research report on Friday, February 20th. Mizuho began coverage on GRAIL in a research note on Friday. They issued a “neutral” rating and a $58.00 price objective on the stock. Piper Sandler began coverage on GRAIL in a research note on Friday. They set a “neutral” rating and a $54.00 target price for the company. Finally, Wall Street Zen downgraded GRAIL from a “hold” rating to a “sell” rating in a research note on Saturday. Four research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $68.63.

Institutional Trading of GRAIL

Several hedge funds have recently added to or reduced their stakes in the business. WIM INVESTMENT MANAGEMENT Ltd grew its position in GRAIL by 200.0% in the 3rd quarter. WIM INVESTMENT MANAGEMENT Ltd now owns 63,000 shares of the company’s stock worth $3,725,000 after purchasing an additional 42,000 shares during the last quarter. JPMorgan Chase & Co. grew its position in GRAIL by 159.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 206,120 shares of the company’s stock worth $12,188,000 after purchasing an additional 126,576 shares during the last quarter. Farallon Capital Management LLC grew its position in GRAIL by 168.7% in the 3rd quarter. Farallon Capital Management LLC now owns 1,349,000 shares of the company’s stock worth $79,766,000 after purchasing an additional 847,000 shares during the last quarter. Caxton Associates LLP acquired a new stake in GRAIL in the 2nd quarter worth $3,320,000. Finally, NWF Advisory Services Inc. acquired a new stake in GRAIL in the 2nd quarter worth $1,062,000.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.